Corrigendum to: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States

J Bryan Iorgulescu^{1

2}, Chuxuan Sun³, Corey Neff^{4

5}, Gino Cioffi^{4

6}, Catherine Gutierrez^{1

2}, Carol Kruchko⁴, Jennifer Ruhl⁷, Kristin Waite^{4

6}, Serban Negoita⁷, Jim Hofferkamp⁸, Tarik Tihan⁹, Roger McLendon^{10

11

12}, Daniel J Brat¹³, Quinn T Ostrom^{4

5

11

12}, Jill S Barnholtz-Sloan^{4

6

14}

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School.
² Department of Medical Oncology, Dana-Farber Cancer Institute.
³ Department of Biostatistics, Duke University School of Medicine.
⁴ Central Brain Tumor Registry of the United States.
⁵ Department of Neurosurgery, Duke University School of Medicine.
⁶ Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.
⁷ Surveillance, Epidemiology, and End Results program, National Cancer Institute.
⁸ North American Association of Central Cancer Registries.
⁹ Division of Neuropathology, Department of Pathology, University of California San Francisco.
¹⁰ Department of Pathology, Duke University School of Medicine.
¹¹ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine.
¹² Duke Cancer Institute, Duke University Medical Center.
¹³ Department of Pathology, Northwestern University Feinberg School of Medicine.
¹⁴ Center for Biomedical Informatics & Information Technology, National Cancer Institute.

Published Erratum

J Bryan Iorgulescu et al. Neuro Oncol. 2023.

. 2023 Feb 14;25(2):424-429.

doi: 10.1093/neuonc/noac270.

¹ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School.
² Department of Medical Oncology, Dana-Farber Cancer Institute.
³ Department of Biostatistics, Duke University School of Medicine.
⁴ Central Brain Tumor Registry of the United States.
⁵ Department of Neurosurgery, Duke University School of Medicine.
⁶ Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute.
⁷ Surveillance, Epidemiology, and End Results program, National Cancer Institute.
⁸ North American Association of Central Cancer Registries.
⁹ Division of Neuropathology, Department of Pathology, University of California San Francisco.
¹⁰ Department of Pathology, Duke University School of Medicine.
¹¹ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine.
¹² Duke Cancer Institute, Duke University Medical Center.
¹³ Department of Pathology, Northwestern University Feinberg School of Medicine.
¹⁴ Center for Biomedical Informatics & Information Technology, National Cancer Institute.

No abstract available

Erratum for

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite KA, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS. Iorgulescu JB, et al. Neuro Oncol. 2022 Nov 2;24(11):1989-2000. doi: 10.1093/neuonc/noac113. Neuro Oncol. 2022. PMID: 35460555 Free PMC article.